• If you are wondering whether ANI Pharmaceuticals at around US$80 per share offers good value today, its recent performance and valuation checks give you a useful starting point.
• The stock last closed at US$80.14, with returns of 8.0% over the past week, 5.5% over the past month, 2.2% year to date and 23.1% over the past year, alongside very large gains over the past 3 and 5 years.
• Recent news coverage has focused on ANI Pharmaceuticals as a US based pharmaceutical company listed on the Nasdaq and tracked by valuation platforms that regularly update their fair value estimates. This ongoing attention helps frame how investors are thinking about its current price and potential risks.
• On Simply Wall St's 6 point valuation framework, ANI Pharmaceuticals currently scores 3 out of 6. The next sections will compare the different valuation methods behind that number and then provide a broader way to think about what the stock is really worth.

Approach 1: ANI Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to the present.

For ANI Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in US$. The latest twelve month free cash flow is about $154.2 million. Analysts provide free cash flow estimates out to 2027, and Simply Wall St then extrapolates these further. Under these projections, free cash flow is expected to reach around $421.5 million in 2035, with interim projected figures for each year in between.

After discounting all those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $400.08 per share. Compared with the recent share price of roughly $80, this implies the stock is about 80.0% undervalued on this model.

This is a large gap, so if you put weight on long term cash flow forecasts, the DCF view suggests ANI Pharmaceuticals could be trading well below its modeled value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests ANI Pharmaceuticals is undervalued by 80.0%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: ANI Pharmaceuticals Price vs Earnings

For a profitable company like ANI Pharmaceuticals, the P/E ratio is a useful way to relate what you pay per share to the earnings that each share generates. Investors usually accept a higher P/E if they expect stronger earnings growth or see the business as lower risk, while slower growth or higher uncertainty tends to justify a lower, more cautious P/E.

ANI Pharmaceuticals currently trades on a P/E of 23.83x. That compares with a Pharmaceuticals industry average P/E of about 17.21x and a peer group average of 15.26x, so the shares are priced at a higher multiple of earnings than these broad benchmarks.

Simply Wall St also calculates a proprietary “Fair Ratio” for ANI Pharmaceuticals of 18.18x. This aims to estimate what a reasonable P/E might be given the company’s earnings growth profile, profit margins, industry, market cap and key risks. Because it is tailored to the company, this Fair Ratio can be more informative than a simple comparison with industry or peer averages, which do not adjust for those specific characteristics. On this measure, ANI Pharmaceuticals trades above its Fair Ratio, which indicates that the stock may be overvalued using the P/E approach.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your ANI Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring that to life by letting you attach a clear story to the numbers, linking your view on ANI Pharmaceuticals future revenue, earnings and margins to a forecast and then to a fair value that you can compare with the current price.

On Simply Wall St's Community page, Narratives are easy to use. They sit on the same platform used by millions of investors, and they update automatically when new information such as earnings releases, guidance changes or news headlines is added, so your fair value view keeps reflecting the latest data.

For ANI Pharmaceuticals, one investor might build a more cautious Narrative that lines up with a fair value of about US$90 per share, while another might prefer a more optimistic Narrative closer to US$120. By setting up either view you can see at a glance whether your fair value sits above or below the current share price and then decide for yourself whether that gap justifies a buy, hold or sell decision.

Do you think there's more to the story for ANI Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.